Kalytera

• Category: Pharma
• Investment Status: IPO
• Medical Field: Oncology
• Patent Status: National phase. Granted in several regions
• Development Status: clinical trials
• Medical Center: Rabin Medical Center

• Inventors: Dr. Moshe Yeshurun
  

Kalytera Therapeutics is a clinical-stage pharmaceutical company developing cannabinoid therapeutics. Through its proven leadership, drug development expertise, and growing intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease (“GvHD”).